All In Biotech

Drug Trial Radar · NCT02026063

Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms

A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)

Last checked: Nov 20, 2026Latest source record: Sep 17, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

124

Actual

Start

Jan 14, 2014

Primary completion

Sep 12, 2018

Study completion Sep 12, 2018

Sponsor

Lead sponsor
Lexicon PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jan 1, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate.

Conditions

  • Carcinoid Syndrome

Interventions

  • Telotristat etiprateDrug

    Telotristat etiprate tablet (250 mg)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose of study drug (Day 1) up to 15 days post last dose (approximately up to 236 weeks)

Locations

43 sites in 12 countries. Site status is shown where the registry gives one.

  • Lexicon Investigational Site

    Mobile, Alabama

  • Lexicon Investigational Site

    Stanford, California

  • Lexicon Investigational Site

    Iowa City, Iowa

  • Lexicon Investigational Site

    Lexington, Kentucky

  • Lexicon Investigational Site

    Boston, Massachusetts

  • Lexicon Investigational Site

    New York, New York

  • Lexicon Investigational Site

    Philadelphia, Pennsylvania

  • Lexicon Investigational Site

    St Leonards, New South Wales, Australia

  • Lexicon Investigational Site

    Herston, Queensland, Australia

  • Lexicon Investigational Site

    East Melbourne, Victoria, Australia

  • Lexicon Investigational Site

    Edegem, Belgium

  • Lexicon Investigational Site

    Ghent, Belgium

  • Lexicon Investigational Site

    Yvoir, Belgium

  • Lexicon Investgational Site

    Calgary, Alberta, Canada

  • Lexicon Investigational Site

    Halifax, Nova Scotia, Canada

  • Lexicon Investigational Site

    Lille, France

  • Lexicon Investigational Site

    Lyon, France

  • Lexicon Investigational Site

    Villejuif, France

  • Lexicon Investigational Site

    Bad Berka, Germany

  • Lexicon Investigational Site

    Berlin, Germany

  • Lexicon Investigational Site

    Essen, Germany

  • Lexicon Investigational Site

    Hamburg, Germany

  • Lexicon Investigational Site

    Marburg, Germany

  • Lexicon Investigational Site

    Jerusalem, Israel

  • Lexicon Investigational Site

    Milan, Italy

  • Lexicon Investigational Site

    Milan, Italy

  • Lexicon Investigational Site

    Pisa, Italy

  • Lexicon Investigational Site

    Torino, Italy

  • Lexicon Investigational Site

    Amsterdam, Netherlands

  • Lexicon Investigational Site

    Noord Holland, Netherlands

  • Lexicon Investigational Site

    Noord-Brahant, Netherlands

  • Lexicon Investigational Site

    Barcelona, Spain

  • Lexicon Investigational Site

    Madrid, Spain

  • Lexicon Investigational Site

    Seville, Spain

  • Lexicon Investigational Site

    Lund, Sweden

  • Lexicon Investigational Site

    Uppsala, Sweden

  • Lexicon Investigational Site

    Coventry, United Kingdom

  • Lexicon Investigational Site

    Glasgow, United Kingdom

  • Lexicon Investigational Site

    London, United Kingdom

  • Lexicon Investigational Site

    London, United Kingdom

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.